Newamsterdam Pharma Company N.V. (NAMS) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Newamsterdam Pharma Company N.V. faces a business risk due to the significant influence of its principal shareholders and management over the company’s Ordinary Shares. As of December 31, 2024, these insiders beneficially owned approximately 49.7% of the outstanding shares, allowing them to significantly influence decisions requiring shareholder or director approval. This influence could impede changes in control or deter potential acquirers, potentially affecting the market price of the shares and preventing shareholders from realizing a premium. Investors should be aware that the interests of these influential shareholders may not align with those of other stakeholders.
Overall, Wall Street has a Strong Buy consensus rating on NAMS stock based on 7 Buys.
To learn more about Newamsterdam Pharma Company N.V.’s risk factors, click here.